Posters –
Immunology and Oncology
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
Theranostic Cancer Biomarker
Rémi PICARD
SATT Sud Est
Matrix metalloproteinase 2 (MMP2) is a predictive biomarker of response to
antiangiogenic therapies in cancer patients:
Technology
Customers / Target market
Industry and competitors
- MMP2 baseline plasma level is associated to objective response, progression free
survival, and overall survival and changes under treatment in patients treated with
bevacizumab for recurrent high-grade glioma.
- Plasma MMP2 change under Bevacizumab treatment may reflect tumor control
40% of patients treated with anti-angiogenic treatments are non-responders, which is a
problem with regard to side effects and high cost of these treatments. No validated
biological markers exist for appropriately selecting patients with cancer for
antiangiogenic therapy.
MPP2 plasma level can be a biomarker for:
 Stratification of patients for clinical trials of anti-angiogenic drugs
 Companion test for anti-angiogenic drugs
N/A
Financing need / Commercial
opportunity
We are currently looking for an industrial partner interested for licensing-in the
technology and/or R&D collaboration (possible co-funding)
IP – Patent situation
Patent WO 2013175429 A1
MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after
therapy in cancer patients
Entry into national phase
Future steps / Milestones
N/A
Further reading
Association of matrix metalloproteinase 2 plasma level with response
and survival in patients treated with bevacizumab for recurrent high-grade glioma,
Rabouret et al, Neuro-Oncology, 2014
Contact person
Elodie
Dormes,
Business
elodie.dormes@sattse.com
Development
Manager,
SATT
Sud
Est,